Results 71 to 80 of about 4,689 (214)

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, Volume 121, Issue 7, Page 1781-1793, July 2026.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).

, 2016
1-Propionyl-d-lysergic acid diethylamide hemitartrate (1P-LSD) has become available as a 'research chemical' in the form of blotters and powdered material.
Folker Westphal, Alexander Stratford, Simon D. Brandt, Kavanagh, PV, Simon P. Elliott, Halberstadt, AL, Elliott, SP, Jason Wallach, Hoang, K, Stratford, A, Brandt, SD, Westphal, F, Wallach, J, Khoa Hoang, Adam L. Halberstadt, Pierce V. Kavanagh   +15 more
core   +1 more source

Treatment of neuropathic pain with repeated low-dose MDMA: a case report

Frontiers in Psychiatry
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and high doses and microdoses of ...
Peter Gasser, Matthias E. Liechti, Friederike Holze   +2 more
doaj   +1 more source

A mood disorder episode with an onset under chronic cannabis consumption and accompanied with psychotic features immediately after N, N-Dimethyltryptamine (DMT) use: a case report [PDF]

Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi, 2011
, N-dimethyltryptamine (DMT) is a serotonin agonist hallucinogen, similar to lysergic acid diethylamide (LSD). Syntetic production of DMT as well as extraction from several plants of South American flora is possible.
Güliz Özgen, İlker Küçükparlak, Gökhan Umut, Ahmet Türkcan   +3 more
doaj  

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, Volume 183, Issue 14, Page 4048-4057, July 2026.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects

Frontiers in Pharmacology, 2017
Rationale: Renewed interest has been seen in the use of lysergic acid diethylamide (LSD) in psychiatric research and practice. The repeated use of LSD leads to tolerance that is believed to result from serotonin (5-HT) 5-HT2A receptor downregulation.
Patrick C. Dolder, Edna Grünblatt, Edna Grünblatt, Edna Grünblatt, Felix Müller, Stefan J. Borgwardt, Matthias E. Liechti   +6 more
doaj   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, Volume 183, Issue 14, Page 3935-3949, July 2026.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Acute Lysergic Acid Diethylamide Does Not Influence Reward-Driven Decision Making of C57BL/6 Mice in the Iowa Gambling Task

Frontiers in Pharmacology, 2020
While interest in psychedelic drugs in the fields of psychiatry and neuroscience has re-emerged in recent last decades, the general understanding of the effects of these drugs remains deficient.
Lauri V. Elsilä, Nuppu Korhonen, Petri Hyytiä, Esa R. Korpi   +3 more
doaj   +1 more source